Interferon Beta-1a (Rebif)
Interferon beta-1a (Rebif) is a medication administered by subcutaneous (SC) injection, three times a week for two weeks, then three times a week for two weeks, then three times a week thereafter, for the treatment of relapsing forms of MS. Interferon beta-1a is theorized to down-regulate proinflammatory cytokines, decrease major histocompatibility antigens, and reduce T-lymphocyte passage across the blood brain barrier.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
